<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00066378</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-10021</org_study_id>
    <secondary_id>EORTC-10021</secondary_id>
    <secondary_id>IDBBC-10021</secondary_id>
    <nct_id>NCT00066378</nct_id>
  </id_info>
  <brief_title>Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer</brief_title>
  <official_title>An EORTC Randomized, Double Blind, Placebo-Controlled, Phase II Multi-Center Trial Of Anastrozole (Arimidex) In Combination With ZD 1839 (Iressa) Or Placebo In Patients With Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using&#xD;
      anastrozole may fight breast cancer by reducing the production of estrogen. Gefitinib may&#xD;
      stop the growth of tumor cells by blocking the enzymes necessary for their growth. Combining&#xD;
      anastrozole with gefitinib may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to compare the effectiveness of anastrozole with or&#xD;
      without gefitinib in treating postmenopausal women who have metastatic or locally recurrent&#xD;
      breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the 1 year antitumor activity of anastrozole with vs without gefitinib, in terms&#xD;
           of progression-free survival, in postmenopausal women with metastatic or locally&#xD;
           recurrent advanced breast cancer.&#xD;
&#xD;
        -  Compare the objective tumor response and duration of tumor response in patients treated&#xD;
           with these regimens.&#xD;
&#xD;
        -  Compare the progression-free survival of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the safety of these regimens in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients&#xD;
      are stratified according to participating center, dominant site of metastatic disease (bone&#xD;
      alone vs other), prior chemotherapy (no vs yes), stage (metastatic vs locally recurrent), and&#xD;
      measurability (measurable vs evaluable). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral anastrozole and oral gefitinib once daily.&#xD;
&#xD;
        -  Arm II: Patients receive oral anastrozole and an oral placebo once daily. In both arms,&#xD;
           treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 8 weeks until disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 108 patients (54 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival at 1 year</measure>
    <time_frame>at 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response as measured by RECIST</measure>
    <time_frame>from randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response as measured by RECIST</measure>
    <time_frame>response duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as measured by CTC v2.0</measure>
    <time_frame>from randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arimidex + Iressa速 250 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arimidex + Iressa速 250 mg Treatment should be administered until documented disease progression, unacceptable toxicity as judged by the responsible physician or patient refusal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arimidex + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment should be administered until documented disease progression, unacceptable toxicity as judged by the responsible physician or patient refusal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anastrozole</intervention_name>
    <arm_group_label>Arimidex + Iressa速 250 mg</arm_group_label>
    <arm_group_label>Arimidex + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
    <arm_group_label>Arimidex + Iressa速 250 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed breast cancer&#xD;
&#xD;
               -  Radiologically or clinically evident metastatic or locally recurrent disease&#xD;
&#xD;
               -  Locally advanced disease in elderly patients&#xD;
&#xD;
               -  Bone metastases only allowed&#xD;
&#xD;
          -  Failed prior tamoxifen therapy&#xD;
&#xD;
          -  No rapidly progressive visceral metastases&#xD;
&#xD;
          -  No uncontrolled CNS metastases&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Estrogen receptor and/or progesterone receptor positive&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Postmenopausal&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Postmenopausal, defined by any of the following:&#xD;
&#xD;
               -  Natural menopause with last menses more than 1 year ago&#xD;
&#xD;
               -  Radiotherapy-induced oophorectomy with last menses more than 1 year ago&#xD;
&#xD;
               -  Chemotherapy-induced menopause with last menses more than 1 year ago AND serum&#xD;
                  follicle-stimulating hormone and luteinizing hormone and plasma estradiol levels&#xD;
                  clearly in the postmenopausal range&#xD;
&#xD;
               -  Surgical castration&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Transaminases no greater than 2.5 times ULN&#xD;
&#xD;
          -  No unstable or uncompensated hepatic disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  No unstable or uncompensated renal disease&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No unstable or uncompensated cardiac disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No unstable or uncompensated pulmonary disease&#xD;
&#xD;
          -  No clinically active interstitial lung disease&#xD;
&#xD;
               -  Asymptomatic chronic stable radiographic changes are allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No severe or uncontrolled systemic disease&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated carcinoma in&#xD;
             situ of the cervix, nonmelanoma skin cancer, or contralateral breast cancer&#xD;
&#xD;
          -  No psychological, familial, sociological or geographical condition that would preclude&#xD;
             study compliance and follow-up&#xD;
&#xD;
          -  No grade 2 or greater unresolved chronic toxicity from prior anticancer therapy&#xD;
&#xD;
          -  No unresolved ocular inflammation or infection&#xD;
&#xD;
          -  No known hypersensitivity to anastrozole or gefitinib or any of their excipients&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior trastuzumab (Herceptin)&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No more than 1 line of prior chemotherapy in the adjuvant or metastatic setting&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 2 years since prior aromatase inhibitors (e.g., anastrozole, letrozole, or&#xD;
             exemestane) in the adjuvant setting&#xD;
&#xD;
          -  Prior tamoxifen or fulvestrant in the adjuvant and/or metastatic setting allowed&#xD;
&#xD;
          -  No prior aromatase inhibitors for metastatic disease&#xD;
&#xD;
          -  No other concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy to any metastatic site&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No surgery during and within 4 days after the last dose of gefitinib&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 30 days since prior investigational drugs&#xD;
&#xD;
          -  No prior anti-epidermal growth factor therapy&#xD;
&#xD;
          -  No prior anti-vascular endothelial growth factor therapy (i.e., tyrosine kinase&#xD;
             inhibitor receptor)&#xD;
&#xD;
          -  No concurrent administration of any of the following drugs:&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Hypericum perforatum (St John's Wort)&#xD;
&#xD;
          -  No other concurrent investigational drugs or treatment&#xD;
&#xD;
          -  No other concurrent cancer treatment&#xD;
&#xD;
          -  No concurrent systemic retinoids&#xD;
&#xD;
          -  Concurrent bisphosphonate therapy for the treatment and prevention of bony metastases&#xD;
             is allowed provided therapy was initiated prior to study entry&#xD;
&#xD;
               -  Bisphosphonates may be initiated during study only for the treatment of&#xD;
                  hypercalcemia&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martine J. Piccart, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Jules Bordet Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ziekenhuis Netwerk Antwerpen Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <zip>B-2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Sint-Augustinus</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum St. Radboud - Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>NL-6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology - Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>Sl-1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edinburgh Cancer Centre at Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Slovenia</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Mauriac L, Cameron D, Dirix L: Results of randomized phase II trial combining Iressa (gefitinib) and arimidex in women with advanced breast cancer (ABC): EORTC protocol 10021. [Abstract] 31st Annual San Antonio Breast Cancer Symposium, December 10-14, 2008, San Antonio, Texas. A-6133, 2008.</citation>
  </results_reference>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>August 6, 2003</study_first_submitted>
  <study_first_submitted_qc>August 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2003</study_first_posted>
  <last_update_submitted>October 23, 2013</last_update_submitted>
  <last_update_submitted_qc>October 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

